blank
blank
EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.

EMA public consultation on non‑human primate use in safety testing

Non-human primate hand via pickpik.com (CC0)

The European Medicines Agency (EMA) has launched a public consultation on a draft “Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation”.

The reflection paper provides an overview of the scientific and regulatory considerations for using non‑human primates (NHPs) in the safety testing of human medicinal products. It reviews current uses, highlights existing flexibility in applying the 3Rs principles (Replacement, Reduction and Refinement), and points to emerging alternatives that could further reduce or replace NHP use in the future.

NHPs should be used for regulatory safety testing only as a last resort. The document outlines current opportunities to reduce, refine or replace their use in pharmaceutical development and describes scientific advances that may soon gain broader regulatory acceptance.

Progress in novel, including non‑animal, approaches is scientifically and ethically essential and will depend on continued innovation, collaboration and proactive regulatory engagement.

The draft document is open for consultation, and stakeholders can provide input until 31 January 2026 via the EMA website: Non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation – scientific guideline.

News & Updates

You might also be interested in

European Human Genetics Conference - Rotterdam, The Netherlands June 12-15, 2027

European Human Genetics Conference 2027

June 12 - June 15
The conference will take place in Rotterdam on 12–15 June 2027 and is planned as a hybrid event by the European Society of Human Genetics.
uropean Human Genetics Conference (ESHG) 2026

At ESHG 2026 in Gothenburg, ERDERA’s diagnostics work reviewed early progress and the next phase ahead

At the European Human Genetics Conference 2026 in Gothenburg, ERDERA’s Diagnostic Research Workstream reviewed progress, highlighted early results and used a major European genetics meeting to examine how advances in data sharing and genomic analysis may strengthen rare disease diagnosis across countries.
WODC Boston 2026

At World Orphan Drug Congress USA, ERDERA highlights how connected clinical research networks can make rare disease trials more feasible

Boston, 9–11 June 2026: ERDERA's Scientific Coordinator joined the World Orphan Drug Congress USA to set out how stronger clinical research networks can make rare disease trials more feasible across sites and borders.
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.

ERDERA's

search form